查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1597832

全身性紅斑性狼瘡市場：按藥物類型、給藥方法分類 - 全球預測 2025-2030

Systemic Lupus Erythematosus Market by Drug Type (Antimalarial Drugs, B-Cell Modulators, Biologics), Mode of Delivery (Intravenous, Oral, Subcutaneous) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年全身性紅斑性狼瘡市值為20.4億美元，預計2024年將達22.4億美元，複合年成長率為10.54%，預計到2030年將達到41.2億美元。

全身性紅斑性狼瘡(SLE) 是自體免疫疾病，其特徵是免疫系統攻擊健康組織，引起身體各個系統的發炎和損傷。了解 SLE 市場的必要性在於疾病的不可預測性，以及由於其慢性進展而需要增強的治療選擇。這種需求正在推動精準醫學、生物製藥和個人化治療方法的應用，使它們與醫療保健提供者和患者越來越相關。最終用途範圍主要包括專注於創新治療解決方案的醫院、診所和研究機構。推動市場開拓的關鍵因素包括盛行率上升、意識增強以及促進開發新藥的生物技術進步。此外，診斷技術的改進正在擴大早期檢測和開始治療的範圍，為涉足早期療育解決方案的市場參與者創造了有利可圖的機會。

主要市場統計
基準年[2023] 20.4億美元
預測年份 [2024] 22.4億美元
預測年份 [2030] 41.2億美元
複合年成長率（%） 10.54%

目前 SLE 市場的潛在機會是生物製藥和標靶治療的成長，正在進行的研究為更有效的治療和症狀管理鋪平了道路。創建以患者為中心的干涉措施並與技術進步保持一致，例如利用人工智慧進行藥物發現，是利用這些趨勢的策略領域。儘管有這樣的成長路徑，但市場仍面臨重大挑戰，包括高昂的開發成本、監管障礙以及由於患者異質性而導致進行臨床試驗的複雜性。專利到期也可能影響市場動態，需要配方和藥物輸送系統的創新。

為了實現業務成長和創新，公司應優先考慮個人化醫療的生物標記發現、副作用較少的治療方法以及利用現有和新型治療方法的聯合治療研究等領域。 SLE 市場的本質是高度競爭和監管，成功應對這些挑戰需要強大的研發投資和策略聯盟。了解法律規範並投資加強臨床開發能力是維持市場定位和成長的重要步驟。

市場動態：快速發展的全身性紅斑性狼瘡市場的關鍵市場洞察

全身性紅斑性狼瘡市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 全身性紅斑性狼瘡的全球盛行率不斷上升
    • 提高對發炎自體免疫疾病和治療的認知
    • 改善醫療基礎設施和狼瘡治療診所
  • 市場限制因素
    • 低收入國家治療成本上升和基礎設施缺乏
  • 市場機會
    • 對狼瘡研究工作的大量資助和投資
    • 治療技術的進步與新產品的推出
  • 市場挑戰
    • 治療併發症和管理 SLE 的其他困難

波特五力：駕馭全身性紅斑性狼瘡市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解全身性紅斑性狼瘡市場的外部影響

外部宏觀環境因素在塑造全身性紅斑性狼瘡市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解全身性紅斑性狼瘡市場的競爭狀況

全身性紅斑性狼瘡市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣全身性紅斑性狼瘡市場供應商的績效評估

FPNV定位矩陣是評估全身性紅斑性狼瘡市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製全身性紅斑性狼瘡市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，全身性紅斑性狼瘡市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球全身性紅斑性狼瘡盛行率增加
      • 提高對發炎自體免疫疾病和治療的認知
      • 改善醫療基礎設施和狼瘡治療診所
    • 抑制因素
      • 低收入國家治療成本上升和基礎設施缺乏
    • 機會
      • 對狼瘡研究工作的大量資助和投資
      • 治療技術的進步與新產品的推出
    • 任務
      • 治療併發症和管理 SLE 的其他困難
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章全身性紅斑性狼瘡市場藥物類型

  • 抗瘧疾藥
    • Chloroquine
    • Chloroquine
  • B細胞調變器
  • 生物製藥
    • 核准用於治療 SLE 的生物製藥
      • B細胞標靶治療
      • Bryce 阻斷劑（貝利尤單抗）
    • 仿單標示外使用的生物製藥
  • 細胞毒性和免疫抑制藥物
    • Cyclophosphamide
    • Cyclosporine
    • 胺基甲基葉酸
    • Mycophenolate Mofetil或Tacrolimus
  • 免疫抑制劑、細胞毒藥物、T細胞調節劑
  • 非類固醇消炎劑
  • 發炎和細胞激素抑制劑

第7章以交付方式分類的全身性紅斑性狼瘡市場

  • 靜脈
  • 口服
  • 皮下的
  • 話題

第8章北美和南美全身性紅斑性狼瘡市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區全身性紅斑性狼瘡市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲的全身性紅斑性狼瘡市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbvie, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Aurinia Pharmaceuticals Inc.
  • bioMerieux SA
  • Boston Pharmaceuticals Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Hoffmann-LA-Roche Ltd.
  • ImmuPharma PLC
  • Mylan NV
  • Novartis AG
  • Pfizer, Inc.
  • Xencor, Inc.
Product Code: MRR-957C47F944B9

The Systemic Lupus Erythematosus Market was valued at USD 2.04 billion in 2023, expected to reach USD 2.24 billion in 2024, and is projected to grow at a CAGR of 10.54%, to USD 4.12 billion by 2030.

Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by the immune system attacking healthy tissues, leading to inflammation and damage across various body systems. The necessity of understanding the SLE market lies in the need for enhanced therapeutic options due to the disease's unpredictable nature and chronic progression. This demand is driving the application of precision medicine, biologics, and personalized treatment regimens, which are becoming increasingly relevant for both healthcare providers and patients. The end-use scope primarily involves hospitals, clinics, and research institutions focusing on innovative treatment solutions. Key market growth influencers include rising prevalence rates, increased awareness, and advancements in biotechnology facilitating novel drug development. Additionally, improved diagnostic techniques are expanding earlier detection and treatment initiation, presenting lucrative opportunities for market players to venture into early intervention solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 2.04 billion
Estimated Year [2024] USD 2.24 billion
Forecast Year [2030] USD 4.12 billion
CAGR (%) 10.54%

Current potential opportunities in the SLE market embrace growth in biologics and targeted therapies, with ongoing research paving the way for more effective treatments and symptom management. The creation of patient-focused interventions and alignment with technological advancements, such as using AI for drug discovery, are strategic areas for capitalizing on these trends. Despite these growth avenues, the market faces significant challenges, including high development costs, regulatory hurdles, and the complexity of conducting clinical trials due to patient heterogeneity. Patent expirations may also impact market dynamics, necessitating innovation in drug formulations and delivery systems.

For business growth and innovation, companies should prioritize areas such as biomarker discovery for personalized medicine, reduced side-effect therapies, and research into combination therapies that leverage existing and new modalities. The SLE market's nature is highly competitive and regulated, necessitating robust R&D investments and strategic partnerships to navigate these challenges successfully. Understanding regulatory frameworks and investing in enhancing clinical development capabilities are essential steps to ensure sustained market positioning and growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Systemic Lupus Erythematosus Market

The Systemic Lupus Erythematosus Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of systemic lupus erythematosus worldwide
    • Rising awareness of inflammatory autoimmune diseases and treatment
    • Improvement in healthcare infrastructure and lupus treatment clinics
  • Market Restraints
    • High cost of treatment and lack of infrastructure in low-income countries
  • Market Opportunities
    • Significant funding and investment for lupus research activities
    • Advancement in treatment technologie and launch of new products
  • Market Challenges
    • Complications in treatment and other difficulties in managing SLE

Porter's Five Forces: A Strategic Tool for Navigating the Systemic Lupus Erythematosus Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Systemic Lupus Erythematosus Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Systemic Lupus Erythematosus Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Systemic Lupus Erythematosus Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Systemic Lupus Erythematosus Market

A detailed market share analysis in the Systemic Lupus Erythematosus Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Systemic Lupus Erythematosus Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Systemic Lupus Erythematosus Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Systemic Lupus Erythematosus Market

A strategic analysis of the Systemic Lupus Erythematosus Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Systemic Lupus Erythematosus Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Amgen Inc., AstraZeneca PLC, Aurinia Pharmaceuticals Inc., bioMerieux SA, Boston Pharmaceuticals Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline PLC, Hoffmann-LA-Roche Ltd., ImmuPharma PLC, Mylan N.V., Novartis AG, Pfizer, Inc., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Systemic Lupus Erythematosus Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Antimalarial Drugs, B-Cell Modulators, Biologics, Cytotoxic & Immunosuppressive Drugs, Immunosuppressive & Cytotoxic Drugs & T-Cell Modulators, Non-Steroidal Anti-Inflammatory Drugs, and Pro-Inflammatory & Cytokine Inhibitors. The Antimalarial Drugs is further studied across Chloroquine and Hydrochloroquine. The Biologics is further studied across Approved Biologics for Treating SLE and Biologics Used Off-Label. The Approved Biologics for Treating SLE is further studied across B-Cell Targeted Therapy and Blys-Blockers (Belimumab). The Cytotoxic & Immunosuppressive Drugs is further studied across Cyclophosphamide, Cyclosporine, Methotrexate, and Mycophenolate Mofetil or Tacrolimus.
  • Based on Mode of Delivery, market is studied across Intravenous, Oral, Subcutaneous, and Topical.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of systemic lupus erythematosus worldwide
      • 5.1.1.2. Rising awareness of inflammatory autoimmune diseases and treatment
      • 5.1.1.3. Improvement in healthcare infrastructure and lupus treatment clinics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and lack of infrastructure in low-income countries
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant funding and investment for lupus research activities
      • 5.1.3.2. Advancement in treatment technologie and launch of new products
    • 5.1.4. Challenges
      • 5.1.4.1. Complications in treatment and other difficulties in managing SLE
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Systemic Lupus Erythematosus Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Antimalarial Drugs
    • 6.2.1. Chloroquine
    • 6.2.2. Hydrochloroquine
  • 6.3. B-Cell Modulators
  • 6.4. Biologics
    • 6.4.1. Approved Biologics for Treating SLE
      • 6.4.1.1. B-Cell Targeted Therapy
      • 6.4.1.2. Blys-Blockers (Belimumab)
    • 6.4.2. Biologics Used Off-Label
  • 6.5. Cytotoxic & Immunosuppressive Drugs
    • 6.5.1. Cyclophosphamide
    • 6.5.2. Cyclosporine
    • 6.5.3. Methotrexate
    • 6.5.4. Mycophenolate Mofetil or Tacrolimus
  • 6.6. Immunosuppressive & Cytotoxic Drugs & T-Cell Modulators
  • 6.7. Non-Steroidal Anti-Inflammatory Drugs
  • 6.8. Pro-Inflammatory & Cytokine Inhibitors

7. Systemic Lupus Erythematosus Market, by Mode of Delivery

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral
  • 7.4. Subcutaneous
  • 7.5. Topical

8. Americas Systemic Lupus Erythematosus Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Systemic Lupus Erythematosus Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Systemic Lupus Erythematosus Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie, Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Aurinia Pharmaceuticals Inc.
  • 5. bioMerieux SA
  • 6. Boston Pharmaceuticals Inc.
  • 7. Bristol-Myers Squibb Company
  • 8. Eli Lilly and Company
  • 9. GlaxoSmithKline PLC
  • 10. Hoffmann-LA-Roche Ltd.
  • 11. ImmuPharma PLC
  • 12. Mylan N.V.
  • 13. Novartis AG
  • 14. Pfizer, Inc.
  • 15. Xencor, Inc.

LIST OF FIGURES

  • FIGURE 1. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET RESEARCH PROCESS
  • FIGURE 2. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET DYNAMICS
  • TABLE 7. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY HYDROCHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY B-CELL MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY B-CELL TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BLYS-BLOCKERS (BELIMUMAB), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS USED OFF-LABEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MYCOPHENOLATE MOFETIL OR TACROLIMUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY IMMUNOSUPPRESSIVE & CYTOTOXIC DRUGS & T-CELL MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY PRO-INFLAMMATORY & CYTOKINE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 284. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 285. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, FPNV POSITIONING MATRIX, 2023